{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:43:12Z","timestamp":1791495792608,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients suffering from intractable cancer pain, which cannot be sufficiently relieved even with strong opioid analgesics, methadone is recommended in Japan. However, the real-world data on the efficacy and safety of methadone for intractable pain in patients with lung cancer remain scarce in clinical setting. The aim of this clinical study was to investigate the efficacy and safety of methadone for intractable pain in advanced lung cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All the cases of advanced lung cancer patients who were administered methadone for intractable pain at the Shizuoka Cancer Center between September 2014 and December 2022 were extracted, and their medical information in the electronic medical records were examined. We investigated pain intensity in Numeric Rating Score (NRS) on the day before and 5\u00a0days after the initiation of methadone administration, when methadone blood levels were expected to reach a plateau. In addition, the adverse events possibly caused by methadone were also investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and conclusions<\/jats:title>\n                    <jats:p>Methadone was prescribed for intractable pain in 37 patients with advanced lung cancer during the study period. The leading cause of intractable pain was bone metastasis (including invasion). Both the pain intensity in NRS and the number of rescue doses were significantly reduced by the introduction of methadone (P\u00a0&amp;lt;\u00a0.001). In only two patients, methadone was discontinued due to the side effects thought to be caused by this drug. The results of this study indicated the favorable efficacy and safety profile of methadone for intractable pain in patients with advanced lung cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf175","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:14:44Z","timestamp":1762841684000},"page":"196-201","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy and safety profile of methadone for intractable cancer pain in advanced lung cancer patients: a single-center retrospective analysis of 37 Japanese patients"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-7781","authenticated-orcid":false,"given":"Yuko","family":"Iida","sequence":"first","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]},{"name":"Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine , 30-1 Ohyaguchi-Kamimachi, Itabashi, Tokyo 173-8610 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8445-180X","authenticated-orcid":false,"given":"Tetsumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Palliative Medicine, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2026021308512031900_ref1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"2026021308512031900_ref2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4137\/CMO.S8360","article-title":"Clinical management of pain in advanced lung cancer","volume":"6","author":"Simmons","year":"2012","journal-title":"Clin Med Insights Oncol"},{"key":"2026021308512031900_ref3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0304-3959(87)91033-5","article-title":"Intractable pain with lung cancer","volume":"29","author":"Watson","year":"1987","journal-title":"Pain"},{"key":"2026021308512031900_ref4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40263-020-00743-3","article-title":"Methadone for pain management: a pharmacotherapeutic review","volume":"34","author":"Kreutzwiser","year":"2020","journal-title":"CNS Drugs"},{"key":"2026021308512031900_ref5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12904-022-01076-2","article-title":"Methadone switching for refractory cancer pain","volume":"21","author":"Ding","year":"2022","journal-title":"BMC Palliat Care"},{"key":"2026021308512031900_ref6","first-page":"205","article-title":"New opioid options in Japan - methadone, tapentadol and hydromorphone. Gan to kagaku ryoho","volume":"45","author":"Takagi","year":"2018","journal-title":"Cancer Chemother"},{"key":"2026021308512031900_ref7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0304-3959(99)00073-1","article-title":"An international survey of cancer pain characteristics and syndromes","volume":"82","author":"Caraceni","year":"1999","journal-title":"Pain"},{"key":"2026021308512031900_ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpainsymman.2010.10.261","article-title":"Pain, depression, and fatigue as a symptom cluster in advanced cancer","volume":"42","author":"Laird","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"2026021308512031900_ref9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jpainsymman.2010.10.261","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026021308512031900_ref10","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1200\/JCO.2010.28.6559","article-title":"Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy","volume":"28","author":"Kerba","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026021308512031900_ref11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1212\/wnl.44.5.857","article-title":"Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies","volume":"44","author":"Cherny","year":"1994","journal-title":"Neurology"},{"key":"2026021308512031900_ref12","doi-asserted-by":"publisher","first-page":"CD006146","DOI":"10.1002\/14651858.CD006146.pub2","article-title":"Opioids for neuropathic pain","volume":"2013","author":"McNicol","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021308512031900_ref13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1089\/pmr.2023.0018","article-title":"Differences in the analgesic effect of opioids on pain in cancer patients with spinal metastases","volume":"4","author":"Takemura","year":"2023","journal-title":"Palliat Med Rep"},{"key":"2026021308512031900_ref14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jpainsymman.2017.10.017","article-title":"Methadone as a first-line opioid in cancer pain management: a systematic review","volume":"55","author":"Mercadante","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"2026021308512031900_ref15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jjco\/hyae156","article-title":"Low-dose add-on methadone for cancer pain management: a retrospective analysis of 102 Japanese patients","volume":"55","author":"Sato","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026021308512031900_ref16","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2011.06.005","article-title":"Use of methadone as a coanalgesic","volume":"42","author":"McKenna","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"2026021308512031900_ref17","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.jpainsymman.2011.12.270","article-title":"Use of methadone as a coanalgesic: response to McKenna and Nicholson","volume":"43","author":"Haughey","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"2026021308512031900_ref18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/jpm.2012.0335","article-title":"Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series","volume":"16","author":"Wallace","year":"2013","journal-title":"J Palliat Med"},{"key":"2026021308512031900_ref19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1089\/jpm.2015.0525","article-title":"Methadone as a coanalgesic for palliative care cancer patients","volume":"19","author":"Courtemanche","year":"2016","journal-title":"J Palliat Med"},{"key":"2026021308512031900_ref20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1089\/jpm.2016.0246","article-title":"Use of methadone as an adjuvant medication to low-dose opioids for neuropathic pain in the frail elderly: a case series","volume":"19","author":"Vu Bach","year":"2016","journal-title":"J Palliat Med"},{"key":"2026021308512031900_ref21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/pmr.2020.0034","article-title":"Ultralow-dose adjunctive methadone with slow titration, considering long half-life, for outpatients with cancer-related pain","volume":"1","author":"Chary","year":"2020","journal-title":"Palliat Med Rep"},{"key":"2026021308512031900_ref22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jpm.2017.0157","article-title":"Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment","volume":"21","author":"F\u00fcrst","year":"2018","journal-title":"J Palliat Med"},{"key":"2026021308512031900_ref23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/jpm.2019.0253","article-title":"The use of low-dose methadone as add-on to regular opioid therapy in cancer-related pain at end of life: a national Swedish survey in specialized palliative care","volume":"23","author":"F\u00fcrst","year":"2020","journal-title":"J Palliat Med"},{"key":"2026021308512031900_ref24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/AJP.0000000000000959","article-title":"A randomized controlled trial evaluating the analgesic effect of the combination of methadone with morphine for cancer related pain","volume":"37","author":"Duarte","year":"2021","journal-title":"Clin J Pain"},{"key":"2026021308512031900_ref25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/J354v19n04_05","article-title":"Pharmacokinetics of methadone","volume":"19","author":"Lugo","year":"2005","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026021308512031900_ref26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0304-3959(86)90234-4","article-title":"A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer","volume":"25","author":"Gourlay","year":"1986","journal-title":"Pain"},{"key":"2026021308512031900_ref27","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1001\/archinte.166.12.1280","article-title":"Drug-induced long QT syndrome in injection drug receiving methadone. High frequency in hospitalized patients and risk factors","volume":"166","author":"Ehret","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026021308512031900_ref28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/pmr.2023.0061","article-title":"Safety and efficacy of combined injection of pure-\u03bc-opioid agonist with tramadol as an opioid induction agent for opioid na\u00efve cancer patients","volume":"5","author":"Sato","year":"2024","journal-title":"Palliat Med Rep"},{"key":"2026021308512031900_ref29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/11589080-000000000-00000","article-title":"Tapentadol in pain management: a \u03bc-opioid receptor agonist and noradrenaline reuptake inhibitor","volume":"25","author":"Hartrick","year":"2011","journal-title":"CNS Drugs"},{"key":"2026021308512031900_ref30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40263-014-0151-9","article-title":"The mu-opioid receptor agonist\/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol","volume":"28","author":"Tzschentke","year":"2014","journal-title":"CNS Drugs"},{"key":"2026021308512031900_ref31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1517\/14656566.2012.696097","article-title":"Mechanistic and functional differentiation of tapentadol and tramadol","volume":"13","author":"Raffa","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"2026021308512031900_ref32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/ejp.1196","article-title":"Comparative pharmacology and toxicology of tramadol and tapentadol","volume":"22","author":"Faria","year":"2018","journal-title":"Eur J Pain"},{"key":"2026021308512031900_ref33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00210-015-1167-5","article-title":"What is the main mechanism of tramadol?","volume":"388","author":"Minami","year":"2015","journal-title":"Naunyn Shmiedebergs Arch Pharmacol"},{"key":"2026021308512031900_ref34","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/oncolo\/oyae094","article-title":"Opioid metabolism and drug-drug interaction in cancer","volume":"11","author":"Aapro","year":"2024","journal-title":"Oncologist"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/196\/65267020\/hyaf175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/196\/65267020\/hyaf175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:51:31Z","timestamp":1770990691000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/2\/196\/8320215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf175","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,11]]}}}